BIIB240628P215000
- 1.88
- 0.000.00%
Biogen Newsroom
BMO: Eli Lilly and Co's Alzheimer's drug is expected to generate revenue of $7.1 billion, which is better than Biogen's competitor.
According to BMO reports, eli lilly and co's newly approved Alzheimer's drug donanemab could bring in peak sales of up to $7.1 billion for the company.
Lilly's New Alzheimer's Drug Could Generate $7.1B in Sales: Analyst
Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.Once-monthly, Kisunla is th
Global Equities Roundup: Market Talk
The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day. 1017 ET - Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA on Tuesda
Eli Lilly and Co has finally received approval from the USA's FDA, and there will be a two-horse race in the field of Alzheimer's disease.
Eli Lilly and Co executives wrote that Kisunla has shown a very meaningful effect, and patients urgently need this effective treatment plan.
Biogen Shares Are Trading Lower After the FDA Approved Competitor Eli Lilly's Kisunla for Early Symptomatic Alzheimer's Disease. Pharma Stocks Fell Earlier in the Session After President Biden and Senator Sanders Called on Some Companies to Lower Drug...
Biogen Shares Are Trading Lower After the FDA Approved Competitor Eli Lilly's Kisunla for Early Symptomatic Alzheimer's Disease. Pharma Stocks Fell Earlier in the Session After President Biden and Sen
Express News | US pharmaceutical company Biogen fell 2.8% to an intraday low, after Eli Lilly and Co (LLY.N) announced a delay in the FDA approval of its Alzheimer's drug.
Eli Lilly Wins FDA Approval of Donanemab for Alzheimer's
Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
Express News | Biogen Completes Acquisition of Human Immunology Biosciences
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Cassava Sciences Shares Plunge on Indictment Against Former Advisor -- Barrons.com
By Anita Hamilton A federal indictment of a lead scientist working as an advisor for Cassava Sciences, which has an Alzheimer's drug in late-stage clinical trials, sent shares sharply down Friday. T
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Needham analyst Ami Fadia maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $294.According to TipRanks data, the analyst has a success rate of 43.9% and a total average
Express News | Weiyuan China: Will launch a medical insurance plan for a new pharmaceutical Lunakane monoclonal antibody for Alzheimer's disease.
Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.
Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease
Biogen (BIIB) said Thursday it has launched the humanized anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi in China with Eisai Co. Ltd. Leqembi received approval in January as a treatm
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen